{'fraction_non_alphanumeric': 0.015772870662460567, 'fraction_numerical': 0.0031545741324921135, 'mean_word_length': 5.063694267515924, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Biopharmaceutical Considerations In Topical Ocular Drug Delivery

1. Despite the accessibility of the front of the eye, efficient delivery of drug to treat various ocular disorders is a challenge to the formulation scientist. The majority of ophthalmic medications are formulated as eye drops. Due to anatomical constraints, the volume that can be administered is limited to approximately 30 μL. This, together with the efficient clearance system that exists in the front of the eye, makes it difficult to maintain an effective pre‐ocular drug concentration for a desired length of time. Various formulation strategies have been used to increase pre‐ocular retention of eye drops. The most successful of these has been the inclusion of viscosity enhancing polymers, particularly those able to interact with the mucous layer on the eye surface or those that can undergo a transition from a solution to a gel under the conditions of the pre‐ocular area.